Brief: Larimar Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp

Larimar Therapeutics

12/02/2024 12:43

Feb 12 (Reuters) - Larimar Therapeutics Inc  LRMR.O :
    * LARIMAR THERAPEUTICS REPORTS POSITIVE TOP-LINE DATA FROM
PHASE 2
DOSE EXPLORATION STUDY FROM 25 MG AND 50 MG COHORTS OF
NOMLABOFUSP IN PATIENTS WITH FRIEDREICH’S ATAXIA
    * LARIMAR THERAPEUTICS INC: DOSE DEPENDENT INCREASES IN
FRATAXIN
LEVELS WERE OBSERVED IN SKIN AND BUCCAL CELLS
    * LARIMAR THERAPEUTICS INC: INITIATED DISCUSSIONS WITH FDA
ON USE
OF TISSUE FRATAXIN LEVELS AS A NOVEL SURROGATE ENDPOINT TO
SUPPORT A POTENTIAL BLA
    * LARIMAR THERAPEUTICS INC: NOMLABOFUSP WAS GENERALLY WELL
TOLERATED
    * LARIMAR THERAPEUTICS INC: BIOLOGICS LICENSE APPLICATION
SUBMISSION FOR ACCELERATED APPROVAL TARGETED FOR 2H 2025
    * LARIMAR THERAPEUTICS INC: EXPECT TO PROVIDE INTERIM DATA
FROM
OLE STUDY IN Q4 OF 2024

Source text for Eikon:  ID:nGNX24gSlc 
Further company coverage:  LRMR.O 

 ((Reuters.Briefs@thomsonreuters.com;))